Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study | AVESİS

Hacettepe University Research Information System

Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study

Copy For Citation

Pernas S., Hinojo C., Pascual J., AKSOY S., Clack G., McIntosh S.

Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024, (Summary Text)

Publication Type: Conference Paper / Summary Text
Country: ELECTR NETWORK
Hacettepe University Affiliated: No